In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia

Anti-Cancer Drugs

Volumn 16, Issue 6, 2005, Pages 631-634

  Hallböök, Helene ^a   Barbany, Gisela ^a   Åleskog, Anna ^a   Björnberg, Annelie ^a   Larsson, Rolf ^a   Sundström, Christer ^a   Lindhagen, Elin ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute lymphoblastic leukemia; BCR ABL; Imatinib; In vitro assay

Indexed keywords

ASPARAGINASE; BCR ABL PROTEIN; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; IMATINIB; MERCAPTOPURINE; PREDNISOLONE; PROTEIN P190; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER PATIENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; EVALUATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL;

6-MERCAPTOPURINE; ADULT; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CELL SURVIVAL; CYTARABINE; DAUNORUBICIN; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC, ACUTE; PHILADELPHIA CHROMOSOME; PIPERAZINES; PREDNISOLONE; PYRIMIDINES; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 20844445281     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200507000-00007     Document Type: Article

References (24)

1. Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99:1536-1543.
2. Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992; 80:2983-2990.
3. + leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997; 23:380-394.
4. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90:3691-3698.
5. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with Interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
6. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reitfers J, Silver RT, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100:1965-1971.
7. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038-1042.
8. Larsson R, Kristensen J, Sandberg C, Nygren R Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992; 50:177-185.
9. Frost BM, Nygren P, Gustafsson G, Forestier E, Jonsson OG, Kanerva J, et al. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122:376-385.
10. Gabert J, Beillard E, Van Der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 2003; 17:2318-2357.
11. Barbany G, Hagberg A, Olsson-Stromberg U, Simonsson B, Syvanen AC, Landegren U. Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients. Clin Chem 2000; 46:913-920.
12. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-566.
13. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
14. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247:1079-1082.
15. r 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998; 4:1661-1672.
16. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96:1070-1079.
17. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-880.
18. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103:4396-4407.
19. + ALL). Leukemia 2003; 17;1919-1924.
20. Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000; 96:2246-2253.
21. Avramis IA, Laug WE, Sausville EA, Avramis VI. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother Pharmacol 2003; 52:307-318.
22. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000; 96:3195-3199.
23. Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002; 16:2349-2357.
24. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001; 97:1999-2007.